<DOC>
	<DOCNO>NCT01020786</DOCNO>
	<brief_summary>To investigate efficacy safety combination pemetrexed plus carboplatin , follow pemetrexed patient advance nonsquamous Non Small Cell Lung Cancer ( NSCLC ) receive least one dose induction therapy .</brief_summary>
	<brief_title>A Study Non-squamous Non Small Cell Lung Cancer Asian Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Nonsquamous cell Non Small Cell Lung Cancer ( NSCLC ) disease Clinical stage IIIB/IV recurrent disease surgery No prior systemic chemotherapy , immunotherapy , target therapy biological therapy , include adjuvant therapy Prior radiation therapy allow less 25 % bone marrow Measurable disease define response evaluation criterion solid tumor ( RECIST ) The Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate organ function Estimated life expectancy least 12 week Clinically significant thirdspace fluid collection Central nervous system disease stable treat brain metastasis More 3 week interval surgery enrollment request date Unable interrupt aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) , 5 day period Unable unwilling take folic acid vitamin B12 supplementation Unable take corticosteroid . Serious concomitant disorder , opinion investigator , would compromise patient 's ability adhere protocol Currently historically interstitial pneumonitis ( interstitial pneumonia ) pulmonary fibrosis manifest opacity Chest xray Computed tomography ( CT )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Non-squamous</keyword>
</DOC>